Health Economics of Use Fluoroquinolones to Treat Patients with Community-Acquired Pneumonia

Marcos I. Restrepo, Christopher R. Frei

Research output: Contribution to journalArticle

8 Scopus citations


Respiratory diseases account for approximately 10% of all hospital admissions in the United States. Pneumonia constitutes 35% of these cases, with an average length of stay (LOS) of 5.1 days. It is estimated that $8.4 billion to $10 billion of all annual US hospital expenditures are attributable to community-acquired pneumonia (CAP). As such, medical decisions, including empiric antibiotic choice, potentially exert an impact on hospital LOS and associated costs. In this review, we focus on the empiric antibiotic choices and associated costs of treatment for hospitalized patients with CAP, focusing on the use of fluoroquinolone therapy as recommended by the CAP guidelines.

Original languageEnglish (US)
Pages (from-to)S39-S46
JournalAmerican Journal of Medicine
Issue number4 SUPPL.
Publication statusPublished - Apr 1 2010



  • Fluoroquinolones
  • Macrolides
  • Medical economics
  • Respiratory disorders
  • β-Lactams

ASJC Scopus subject areas

  • Medicine(all)

Cite this